Soliqua Beats Basal Insulin for HbA1c Reduction Regardless of Level at Screening

The Phase 3 trial compared the effectiveness of Soliqua 100/33 and insulin glargine 100 Units/mL in 736 patients
The Phase 3 trial compared the effectiveness of Soliqua 100/33 and insulin glargine 100 Units/mL in 736 patients

This article is part of MPR's coverage of the American Diabetes Association's 77th Scientific Sessions (ADA 2017), taking place in San Diego, CA. Our staff will report on medical research and technological advances in diabetes and diabetes education, conducted by experts in the field. Check back regularly for more news from ADA 2017.


After 30 weeks of treatment, Soliqua 100/33 (insulin glargine + lixisenatide injection; Sanofi) reduced HbA1C by 1.09–2.41% in patients with type 2 diabetes (T2D) previously treated with 15–40 Units of basal insulin daily. Data from the post-hoc analysis of the LixiLan-L Phase 3 study were presented at the American Diabetes Association 77th Scientific Session, San Diego, CA.

The LixiLan-L Phase 3 trial compared the effectiveness of Soliqua 100/33 and insulin glargine 100 Units/mL in 736 patients whose T2D was not adequately controlled at screening on 15–40 units of basal insulin daily, alone or combined with one or two oral anti-diabetic agents. The post-hoc analysis included 660 patients who completed the 30-week study period and grouped patients by HbA1C level at screening: HbA1c ≤8%, HbA1c >8% to ≤9%, and HbA1c >9%. 

After 30 weeks, least squares (LS) mean reductions in HbA1c for the Soliqua 100/33 treatment groups were 1.09%, 1.44% and 2.41%, respectively. In addition, all subgroups reached a mean HbA1c of ≤7% in the Soliqua 100/33 arm (6.65%, 6.99% and 6.97%, respectively) compared to patients in the insulin glargine 100 Units/mL group (7.22%, 7.42% and 7.66%, respectively). Reductions in HbA1c were greater for Soliqua 100/33 in all defined categories vs. insulin glargine 100 Units/mL (P<0.0001 for all comparisons).

With regards to symptomatic hypoglycemia, the incidence of documented (≤70mg/dL / 3.9 mmol/L) events was similar for both the Soliqua 100/33 (40% of patients; 3.0 events/year; E/Y) and insulin glargine 100 Units/mL (42.5% of patients; 4.2 E/Y) groups. 

Soliqua 100/33 is a combination of a long-acting human insulin analog with a glucagon-like peptide (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with T2D inadequately controlled on basal insulin (less than 60 Units daily) or lixisenatide. 

For more information visit Sanofi.us.

Visit MPR's conference section for continuous coverage from ADA 2017


Related Articles